Despite the presence of risk-mitigating recommendations in the medical literature for the care of patients using venetoclax and BTK inhibitors, TLS and GIB remain active concerns for the care of CLL patients, respectively [8,9,10,11,12,13]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.